Ömer Faruk Şahin

Ömer Faruk Şahin

Auto-generated profile, based on publicly available information

Ömer Faruk Şahin

Clinic of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
ÖŞÖmer Faruk Şahin
Ömer Faruk Şahin
ÖFÖzge Erol Fenercioğlu
Özge Erol Fenercioğlu
EBEdiz Beyhan
Ediz Beyhan
TÇTevfik Fikret Çermik
Tevfik Fikret Çermik
NENurhan Ergül
Nurhan Ergül
Neuroendocrine tumors are slow-growing tumors originating from neuroendocrine cells and capable of metastasis. Most of them are found in the gastrointestinal tract; however, they can also be rarely seen in other organs. Testicular neuroendocrine tumors account for less than 1% of all testicular neoplasms. They may present as primary testicular or secondary tumors from extratesticular sources. Jejunal neuroendocrine tumor metastasis to the testis is extremely rare. We present the case of a 61-year-old man with a jejunal neuroendocrine tumor and metastases to bilateral testicles revealed on Gallium-68-DOTATATE positron emission tomography/computed tomography.

7 February 2026 in Journal of Nuclear Cardiology
Verified
Journal Article
Closed access
EAElife Akgün
Elife Akgün
GAGöksel Alçın
Göksel Alçın
ÖŞÖmer Faruk Şahin
Ömer Faruk Şahin
DŞDilruba Şahin
Dilruba Şahin
EKEnes Mustafa Kaya
Enes Mustafa Kaya
EAEsra Arslan
Esra Arslan

19 October 2022 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
GTGamze Tatar
Gamze Tatar
CGCihan Gundogan
Cihan Gundogan
ÖŞÖmer Faruk Şahin
Ömer Faruk Şahin
EAEsra Arslan
Esra Arslan
NENurhan Ergül
Nurhan Ergül
TÇTevfik Fikret Çermik
Tevfik Fikret Çermik
Renal cell carcinoma (RCC) comprises 85%-90% of primary renal malignant tumors originating from the renal tubular epithelium and has different genetic characteristics. This study aimed to investigate the potential predictive role of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and metabolic parameters in overall survival (OS) analysis in patients with RCC. 18F-FDG PET/CT images of 100 patients performed for initial staging before surgical or oncological treatments were analyzed retrospectively. Maximum standard uptake value (SUVmax-T) of the primary tumor was calculated and its relationship to patient survival was analyzed. The median follow-up time was 5.61 years (0.01-8.7 years). SUVmax-T levels in the patients ranged from 2.1 to 48.9 (median 5.9, mean 9.0±7.9). SUVmax-T was significantly higher in RCC-related death more positive than in the negative cases (p<0.001). However, there was not any statistical significance for gender and pathological subtypes on the survival outcomes of patients (p=0.264 and p=0.784). The patients’ 1-year, 3-year, and 5-year OS rates were 71%, 61%, and 57%, respectively. The highest action of SUVmax-T for estimating OS was a cut-off level of 5.4, which maintained sensitivity and specificity of 81% and 75%, respectively. However, cancer staging remained independent significance for OS (p<0.001). SUVmax of primary tumor and cancer stage were demonstrated as significant prognostic factors for OS in patients with RCC. Evaluation of 18F-FDG accumulation with PET/CT may help plan treatment strategies and predict survival outcomes of these patients at diagnosis.

24 March 2026 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
ÖŞÖmer F. Şahin
Ömer F. Şahin
ZTZehranur Tosunoğlu
Zehranur Tosunoğlu
RŞRahime Şahin
Rahime Şahin
DŞDilruba Şahin
Dilruba Şahin
GAGöksel Alçin
Göksel Alçin
TÇTevfik F. Çermik
Tevfik F. Çermik
Objective: This prospective study evaluated the diagnostic performance of 68 Ga DOTA-Pentixafor PET/CT in characterizing the functional properties and lateralization of aldosterone-producing and cortisol-producing adrenal cortical lesions. The contribution of Pentixafor PET/CT to diagnosis and treatment planning was assessed in comparison with CT, MRI, and 18 F-FDG PET/CT. Patients and Methods: Twenty-five patients with suspected benign functional adrenal cortical masses were included. All patients underwent whole-body imaging at 1 hour and delayed abdominal imaging at 2 hours following intravenous administration of 18 F-FDG and 68 Ga DOTA-Pentixafor. Lesion SUVmax, LCRSUVmax, and LLRSUVmax values were analyzed and correlated with laboratory parameters, other imaging modalities, and postoperative clinical and pathologic outcomes. Results: 68 Ga DOTA-Pentixafor PET/CT demonstrated distinct focal uptake relative to the contralateral adrenal gland and liver parenchyma in 6/6 (100%) patients with suspected PA, 5/18 (27.7%) with suspected CS, and 1/1 (100%) with suspected EAS. Among patients with focal uptake who underwent surgery, all PA (5/5) and all CS (5/5) cases were confirmed as adrenocortical adenomas, resulting in no false-positive findings (PPV 100%). However, due to 2 false-negative CS cases, pentixafor PET/CT demonstrated an overall sensitivity of 83.3%, specificity of 100%, and accuracy of 85.7%. Thresholds of SUVmax >15.11, LCRSUVmax >1.74, and LLRSUVmax >4.36 yielded sensitivities of 33.3%, 41.7%, and 41.7%, respectively, while maintaining 100% specificity. Clinical and biochemical improvement was observed in 100% (5/5) of operated PA patients and 100% (5/5) of operated CS patients. Follow-up of nonoperated patients is ongoing. Conclusion: 68 Ga DOTA-Pentixafor PET/CT is a valuable diagnostic and potentially therapeutic tool for benign functional adrenal cortical disorders such as PA, CS, and EAS, with the potential to establish a new standard in minimally invasive patient management.

3 April 2026 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
ÖŞÖmer F. Şahin
Ömer F. Şahin
DŞDilruba Şahin
Dilruba Şahin
ZTZehranur Tosunoğlu
Zehranur Tosunoğlu
Contrast-enhanced abdominal CT of a 57-year-old man presenting with abdominal pain and diarrhea revealed a spiculated, calcified mesenteric mass, initially suggesting a desmoid tumor (DT). The lesion’s ametabolic nature on 18 F-FDG PET/CT supported this suspicion. However, ⁶⁸Ga DOTATATE PET/CT demonstrated intense uptake in both the mesenteric mass, which exhibited a “sunburst” calcification pattern, and the primary ileal focus. Histopathology confirmed an ileal neuroendocrine tumor (NET) with mesenteric lymph node metastasis. This case highlights the critical role of ⁶⁸Ga DOTATATE PET/CT in the differential diagnosis, primary site detection, and accurate staging of FDG-negative mesenteric masses associated with a desmoplastic reaction.

30 July 2026 in Molecular Oncologic Imaging
Verified
Journal Article
Open access
ZTZehranur Tosunoğlu
Zehranur Tosunoğlu
ÖŞÖmer Faruk Şahin
Ömer Faruk Şahin
Primary laryngeal lymphoma is an extremely rare extranodal manifestation of non-Hodgkin lymphoma, accounting for less than 1% of all laryngeal neoplasms. We report a case of isolated primary B-cell lymphoma of the larynx evaluated with 18F-FDG PET/CT imaging. PET/CT demonstrated intense FDG uptake (SUVmax: 16.3) in the laryngeal lesion, while mild FDG uptake (SUVmax: 5.5) was observed in the right palatine tonsil, likely of inflammatory origin. The patient underwent R-CHOP therapy, and both interim and post-treatment PET/CT scans showed complete metabolic and anatomic response. This case highlights the critical role of 18F-FDG PET/CT in the staging and management of rare primary laryngeal lymphomas.